Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niacin ER/Simvastatin vs Atorvastatin in Hyperlipidemia (SUPREME)
NCT00465088Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Apr 2007
- Primary completion
- Feb 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of simvastatin + extended-release niacin in hyperlipidemia and mixed dyslipidemia (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Percent Change in High-density Lipoprotein Cholesterol at 12 weeks. Started Apr 2007; status: completed.
02
Drugs
simvastatin + extended-release niacin
03
Conditions
hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT00465088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00465088.